The YCCC requests continued support for grant related activities that include 9 shared resources, 14 established research programs, 1 developing program and a new clinical trials protocol review and development system. These programs are managed under the direction of four associate directors, working in conjunction with the Director, and an Associate Director, and his administrative staff in four areas: Basic Science, Clinical Science, and Cancer Prevention Research, and Community Research. An Associate Director of Education oversees the Education and training programs of the center. We request continued support for this senior leadership and leaders of established research programs, for planning and evaluation, and developmental funds, and administration. Interdisciplinary coordination in the clinical areas is facilitated by the use of disease oriented units in Breast, GU, GI and Head and Neck cancers; Melanoma, Lymphomas, Brain tumor and a support unit on bone marrow transplantation. Yale's extraordinary depth in Molecular Biology provides focus for the centers translational research. The clinical Research programs are organized around major specialties and have been augmented in this grant cycle by an expanded emphasis on the use of new technology to overcome the major limitations of cancer treatment and prevention by transferring through the means of a shared resource, formerly the tissue retrieval resource, and now the Critical technologies Shared Resource, the capability to include sophisticated molecular technologies in clinical trials in diagnosis, treatment and Prevention, to allow the proper preservation of tissue, and the measurement of both structure and function to correlate with outcome. A new shared resource since the last grant cycle, Clinical Pharmacology, takes advantage of the YCCC's strength in Cancer Pharmacology. Other shared resources include, Flow Cytometry, Animal Tumor Models, Tissue Culture/Media Preparation, Mass Spectrometry, a Cesium-13T Irradiator, and a Transgenic Mouse Shared Resource. The basic research programs in Pathology, Molecular Oncology and Development, Molecular Virology and Cell Biology all emphasize research on oncogenes and suppressor oncogenes vis-a-vis the cell signaling systems. The Program in Immunology focuses on regulation of antigen and growth control processing by T-cells. The Developmental Therapeutics?Chemotherapy Program aims at developing anticancer agents directed at newly identified molecular targets. A developing program in Cancer Genetics will attempt to translate these activities into clinically useful tools.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
5P30CA016359-23
Application #
2442918
Study Section
Cancer Center Support Review Committee (CCS)
Project Start
1977-12-01
Project End
1998-06-30
Budget Start
1997-07-01
Budget End
1998-06-30
Support Year
23
Fiscal Year
1997
Total Cost
Indirect Cost
Name
Yale University
Department
Internal Medicine/Medicine
Type
Schools of Medicine
DUNS #
082359691
City
New Haven
State
CT
Country
United States
Zip Code
06520
Wang, Shi-Yi; Hsu, Sylvia H; Huang, Siwan et al. (2018) Regional Practice Patterns and Racial/Ethnic Differences in Intensity of End-of-Life Care. Health Serv Res 53:4291-4309
Gettinger, S N; Choi, J; Mani, N et al. (2018) A dormant TIL phenotype defines non-small cell lung carcinomas sensitive to immune checkpoint blockers. Nat Commun 9:3196
Liu, Huafeng; Li, Xin; Hu, Li et al. (2018) A crucial role of the PD-1H coinhibitory receptor in suppressing experimental asthma. Cell Mol Immunol 15:838-845
Altwerger, Gary; Bonazzoli, Elena; Bellone, Stefania et al. (2018) In Vitro and In Vivo Activity of IMGN853, an Antibody-Drug Conjugate Targeting Folate Receptor Alpha Linked to DM4, in Biologically Aggressive Endometrial Cancers. Mol Cancer Ther 17:1003-1011
Sanmamed, Miguel F; Chen, Lieping (2018) A Paradigm Shift in Cancer Immunotherapy: From Enhancement to Normalization. Cell 175:313-326
Gupta, Swati; Mani, Navin R; Carvajal-Hausdorf, Daniel E et al. (2018) Macrodissection prior to closed system RT-qPCR is not necessary for estrogen receptor and HER2 concordance with IHC/FISH in breast cancer. Lab Invest 98:1076-1083
Bellone, Stefania; Buza, Natalia; Choi, Jungmin et al. (2018) Exceptional Response to Pembrolizumab in a Metastatic, Chemotherapy/Radiation-Resistant Ovarian Cancer Patient Harboring a PD-L1-Genetic Rearrangement. Clin Cancer Res 24:3282-3291
Altan, Mehmet; Kidwell, Kelley M; Pelekanou, Vasiliki et al. (2018) Association of B7-H4, PD-L1, and tumor infiltrating lymphocytes with outcomes in breast cancer. NPJ Breast Cancer 4:40
Kim, Tae Kon; Herbst, Roy S; Chen, Lieping (2018) Defining and Understanding Adaptive Resistance in Cancer Immunotherapy. Trends Immunol 39:624-631
Goldberg, Sarah B; Patel, Abhijit A (2018) Monitoring immunotherapy outcomes with circulating tumor DNA. Immunotherapy 10:1023-1025

Showing the most recent 10 out of 675 publications